Table 3.
Prevalence of antinuclear-associated autoantibodies in serum and in corresponding immune complexes (IC).
| ANA | Serum | IC | ||||
|---|---|---|---|---|---|---|
| Sudan, n (%) | Sweden, n (%) | P | Sudan, n (%) | Sweden, n (%) | P | |
| SSA/Ro52 | 30(32.2) | 105(31.7) | 0.9 | 18(19.3) | 55(16.6) | 0.5 |
| SSA/Ro60 | 34(36.6) | 122(36.9) | 0.9 | 27(29) | 89(26.8) | 0.7 |
| SSB/La | 15(16.1) | 64(19.3) | 0.5 | 9(9.7) | 38(11.4) | 0.3 |
| Sm | 12(12.9) | 21(6.3) | 0.04 | 6(6.4) | 5(1.5) | 0.008 |
| Sm/U1RNP | 15(16.1) | 42(12.7) | 0.4 | 17(18.3) | 33(9.9) | 0.03 |
| U1RNP | 20(21.5) | 69(20.8) | 0.9 | 22(23.7) | 55(16.6) | 0.1 |
| dsDNA | 31(33.3) | 147(44.4) | 0.055 | 64(68.8) | 105(31.6) | < 0.0001 |
| Histone | 10(10.7) | 34(10.3) | 0.9 | 34(36.6) | 58(17.5) | < 0.0001 |
| Ribosomal P | 4(4.3) | 20(6) | 0.5 | 2(2.1) | 9(2.7) | 0.8 |
| PCNA | 1(1.1) | 10(3) | 0.3 | 20(21.5) | 45(13.5) | 0.06 |
Significant P values are depicted in bold and underlined to indicate higher levels in Sudanese patients.